Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, announced today the publication last week of a manuscript titled “Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: a Retrospective Analysis” in Advances in Therapy, an international, peer-reviewed journal. Read More »

Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for these patients2. Read More »

AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Read More »

Alkermes plc (Nasdaq: ALKS) today announced a new competitive awards program, the ALKERMES Pathways Research AwardsSM Program, which is designed to support the next generation of researchers who are working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders. Read More »

The U.S. Food and Drug Administration (FDA) posted a supply notification about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, on its website to provide greater transparency and confirm that the product remains available. Read More »

“The American Diabetes Association’s new white paper on insulin prices confirms that drugmakers set, and continue to raise, prices. Read More »

Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidence of diabetes Read More »

“Employers, unions, and state health programs hire pharmacy benefit managers (PBMs) to reduce costs for patients by, among other things, negotiating discounts with drug companies and drugstores. Read More »

Sanofi (NYSE: SNY; EURONEXT: SAN) and Regeneron Pharmaceuticals, Inc. today announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts. Read More »

Takeda Pharmaceutical Company Limited (Takeda; TSE: 4502) and H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). Read More »

​Officially approved for leukemia treatment by the FDA just one month ago, Pfizer Inc.’s BESPONSA has gained a primary distributor to provide the drug to pharmacies across the U.S.  Read More »

A generic formulation of AstraZeneca’s Nexium medication that delivers time-released doses of the drug to aid acid-reflux sufferers has received FDA approval and should soon be available for purchase. Read More »

The Rite Aid Foundation recently announced the rollout of its KidCents Safe Medication Disposal Program, which will focus on reducing drug accessibility, medication misuse and accidental poisoning of children and adolescents. Read More »

Novartis recently announced that the U.S. Food and Drug Administration (FDA) approved Kymriah suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Read More »

Coherus BioSciences Inc. of Redwood City, California recently announced initial results from several current clinical pharmacokinetic bioequivalence (PK/BE) studies comparing two products, both developed for the purpose of addressing certain chronic arthritic and skin conditions. Read More »

Endo International plc of Dublin, Ireland recently launched shipping operations for its generic Sabril (vigabatrin for oral solution USP, 500 mg) product via Par Pharmaceutical, following final approval of its Abbreviated New Drug Application (ANDA). Read More »

Orfadin, a drug used to treat a condition causing kidney and liver damage, has now received the FDA’s go-ahead for once-a-day use, cutting its dosing frequency in half. Read More »

Albertsons Cos. plans on continued care for its customers as flu season approaches, reporting from its Boise, Idaho base that influenza vaccines are now in stock. Read More »

Drug developer Ligand Pharmaceuticals Inc. (LGND) of San Diego, California will receive $2 million plus royalties and other benefits from WuXi Biologics in a new licensing agreement involving an antibody technology, company officials announced recently. Read More »

Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More »